Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Gonadorelin

GnRH, Luteinizing Hormone-Releasing Hormone, LHRH, Factrel

Quick Stats
Studies 192
Trials 100
Terminated PHASE4 INTERVENTIONAL NCT01606709

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The purpose of this study is to compare gene expression profiles in endometrial biopsies during the window of implantation after triggers of oocyte maturation using GnRH agonist or hCG and compared with their natural cycles in order to identify genes that may be dysregulated in GnRH agonist-triggered cycles. The investigators also intend to evaluate patients feeling of well being and physical quality of life after GnRH agonist trigger compared with hCG trigger.

Detailed Description

Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication of controlled ovarian hyperstimulation (COH) which may result in significant morbidity and rarely mortality as well as significant financial and psychological distress. The use of a GnRH agonist for induction of final oocyte maturation in ovarian stimulation cycles utilizing GnRH antagonist for pituitary suppression has proven to be an effective method of preventing the risk of OHSS development. Unfortunately, some studies, but not all, have also reported lower pregnancy rates in these cycles as compared to cycles using hCG trigger and this has been attributed to possible impaired endometrial receptivity. The investigators intend to obtain endometrial biopsies collected from the same subject in a natural cycle and then a biopsy during either a GnRH agonist or hCG triggered stimulation. Expression profiles of mRNAs will first be screened using microarray technology. Relative levels of specific mRNAs that display altered expression in the GnRH-triggered samples, as assayed by microarray, will then be confirmed by real-time, quantitative reverse transcription/polymerase chain reaction (Q-PCR). The investigators shall also evaluate patients feeling of well being and physical quality of life after GnRH agonist trigger compared with hCG trigger.

Interventions

Name: GnRH agonist
Type: DRUG
Description: GnRH agonist 1mg one dose
Name: hCG
Type: DRUG
Description: 5,000 IU one dose

Primary Outcomes

Measure: Endometrial Gene Expression Profile
TimeFrame: 7 days after trigger of oocyte maturation
Description: Microarray of gene expression in the midluteal phase

Trial Information

NCT ID

NCT01606709

Status

Terminated

Study Type

INTERVENTIONAL

Phases

PHASE4

Sponsor

UConn Health

Last Updated

December 15, 2025